1
|
Pereira L, Cotas J, Gonçalves AM. Seaweed Proteins: A Step towards Sustainability? Nutrients 2024; 16:1123. [PMID: 38674814 PMCID: PMC11054349 DOI: 10.3390/nu16081123] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2024] [Revised: 04/06/2024] [Accepted: 04/09/2024] [Indexed: 04/28/2024] Open
Abstract
This review delves into the burgeoning field of seaweed proteins as promising alternative sources of protein. With global demand escalating and concerns over traditional protein sources' sustainability and ethics, seaweed emerges as a viable solution, offering a high protein content and minimal environmental impacts. Exploring the nutritional composition, extraction methods, functional properties, and potential health benefits of seaweed proteins, this review provides a comprehensive understanding. Seaweed contains essential amino acids, vitamins, minerals, and antioxidants. Its protein content ranges from 11% to 32% of dry weight, making it valuable for diverse dietary preferences, including vegetarian and vegan diets. Furthermore, this review underscores the sustainability and environmental advantages of seaweed protein production compared to traditional sources. Seaweed cultivation requires minimal resources, mitigating environmental issues like ocean acidification. As the review delves into specific seaweed types, extraction methodologies, and functional properties, it highlights the versatility of seaweed proteins in various food products, including plant-based meats, dairy alternatives, and nutritional supplements. Additionally, it discusses the potential health benefits associated with seaweed proteins, such as their unique amino acid profile and bioactive compounds. Overall, this review aims to provide insights into seaweed proteins' potential applications and their role in addressing global protein needs sustainably.
Collapse
Affiliation(s)
- Leonel Pereira
- Marine Resources, Conservation and Technology, Marine Algae Laboratory, Centre for Functional Ecology—Science for People & the Planet (CFE), Department of Life Sciences, University of Coimbra, 3000-456 Coimbra, Portugal; (J.C.); (A.M.G.)
| | - João Cotas
- Marine Resources, Conservation and Technology, Marine Algae Laboratory, Centre for Functional Ecology—Science for People & the Planet (CFE), Department of Life Sciences, University of Coimbra, 3000-456 Coimbra, Portugal; (J.C.); (A.M.G.)
| | - Ana Marta Gonçalves
- Marine Resources, Conservation and Technology, Marine Algae Laboratory, Centre for Functional Ecology—Science for People & the Planet (CFE), Department of Life Sciences, University of Coimbra, 3000-456 Coimbra, Portugal; (J.C.); (A.M.G.)
- Department of Biology and CESAM—Centro de Estudos do Ambiente e do Mar, University of Aveiro, 3810-193 Aveiro, Portugal
| |
Collapse
|
2
|
Cotas J, Lomartire S, Pereira L, Valado A, Marques JC, Gonçalves AMM. Seaweeds as Nutraceutical Elements and Drugs for Diabetes Mellitus: Future Perspectives. Mar Drugs 2024; 22:168. [PMID: 38667785 PMCID: PMC11051413 DOI: 10.3390/md22040168] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/05/2024] [Revised: 03/26/2024] [Accepted: 03/27/2024] [Indexed: 04/28/2024] Open
Abstract
Diabetes mellitus is a chronic metabolic condition marked by high blood glucose levels caused by inadequate insulin synthesis or poor insulin use. This condition affects millions of individuals worldwide and is linked to a variety of consequences, including cardiovascular disease, neuropathy, nephropathy, and retinopathy. Diabetes therapy now focuses on controlling blood glucose levels through lifestyle changes, oral medicines, and insulin injections. However, these therapies have limits and may not successfully prevent or treat diabetic problems. Several marine-derived chemicals have previously demonstrated promising findings as possible antidiabetic medicines in preclinical investigations. Peptides, polyphenols, and polysaccharides extracted from seaweeds, sponges, and other marine species are among them. As a result, marine natural products have the potential to be a rich source of innovative multitargeted medications for diabetes prevention and treatment, as well as associated complications. Future research should focus on the chemical variety of marine creatures as well as the mechanisms of action of marine-derived chemicals in order to find new antidiabetic medicines and maximize their therapeutic potential. Based on preclinical investigations, this review focuses on the next step for seaweed applications as potential multitargeted medicines for diabetes, highlighting the bioactivities of seaweeds in the prevention and treatment of this illness.
Collapse
Affiliation(s)
- João Cotas
- Marine Resources, Conservation and Technology, Marine Algae Lab, CFE—Centre for Functional Ecology: Science for People & Planet, Department of Life Sciences, University of Coimbra, 3000-456 Coimbra, Portugal; (J.C.); (S.L.); (L.P.)
| | - Silvia Lomartire
- Marine Resources, Conservation and Technology, Marine Algae Lab, CFE—Centre for Functional Ecology: Science for People & Planet, Department of Life Sciences, University of Coimbra, 3000-456 Coimbra, Portugal; (J.C.); (S.L.); (L.P.)
| | - Leonel Pereira
- Marine Resources, Conservation and Technology, Marine Algae Lab, CFE—Centre for Functional Ecology: Science for People & Planet, Department of Life Sciences, University of Coimbra, 3000-456 Coimbra, Portugal; (J.C.); (S.L.); (L.P.)
| | - Ana Valado
- Polytechnic Institute of Coimbra, Coimbra Health School, Biomedical Laboratory Sciences, Rua 5 de Outubro—SM Bispo, Apartado 7006, 3046-854 Coimbra, Portugal;
- Research Centre for Natural Resources, Environment and Society—CERNAS, Escola Superior Agrária de Coimbra Bencanta, 3045-601 Coimbra, Portugal
| | - João Carlos Marques
- MARE—Marine and Environmental Sciences Centre/ARNET-Aquatic Research Network, Department of Life Sciences, University of Coimbra, Calçada Martim de Freitas, 3000-456 Coimbra, Portugal;
| | - Ana M. M. Gonçalves
- Marine Resources, Conservation and Technology, Marine Algae Lab, CFE—Centre for Functional Ecology: Science for People & Planet, Department of Life Sciences, University of Coimbra, 3000-456 Coimbra, Portugal; (J.C.); (S.L.); (L.P.)
- Department of Biology and CESAM, University of Aveiro, 3810-193 Aveiro, Portugal
| |
Collapse
|
3
|
Alhawday F, Alminderej F, Ghannay S, Hammami B, Albadri AEAE, Kadri A, Aouadi K. In Silico Design, Synthesis, and Evaluation of Novel Enantiopure Isoxazolidines as Promising Dual Inhibitors of α-Amylase and α-Glucosidase. Molecules 2024; 29:305. [PMID: 38257218 PMCID: PMC10818600 DOI: 10.3390/molecules29020305] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/29/2023] [Revised: 12/20/2023] [Accepted: 01/04/2024] [Indexed: 01/24/2024] Open
Abstract
Isoxazolidine derivatives were designed, synthesized, and characterized using different spectroscopic techniques and elemental analysis and then evaluated for their ability to inhibit both α-amylase and α-glucosidase enzymes to treat diabetes. All synthesized derivatives demonstrated a varying range of activity, with IC50 values ranging from 53.03 ± 0.106 to 232.8 ± 0.517 μM (α-amylase) and from 94.33 ± 0.282 to 258.7 ± 0.521 μM (α-glucosidase), revealing their high potency compared to the reference drug, acarbose (IC50 = 296.6 ± 0.825 µM and 780.4 ± 0.346 µM), respectively. Specifically, in vitro results revealed that compound 5d achieved the most inhibitory activity with IC50 values of 5.59-fold and 8.27-fold, respectively, toward both enzymes, followed by 5b. Kinetic studies revealed that compound 5d inhibits both enzymes in a competitive mode. Based on the structure-activity relationship (SAR) study, it was concluded that various substitution patterns of the substituent(s) influenced the inhibitory activities of both enzymes. The server pkCSM was used to predict the pharmacokinetics and drug-likeness properties for 5d, which afforded good oral bioavailability. Additionally, compound 5d was subjected to molecular docking to gain insights into its binding mode interactions with the target enzymes. Moreover, via molecular dynamics (MD) simulation analysis, it maintained stability throughout 100 ns. This suggests that 5d possesses the potential to simultaneously target both enzymes effectively, making it advantageous for the development of antidiabetic medications.
Collapse
Affiliation(s)
- Fahad Alhawday
- Department of Chemistry, College of Science, Qassim University, Buraidah 51452, Saudi Arabia; (F.A.); (F.A.); (S.G.); (B.H.); (A.E.A.E.A.)
| | - Fahad Alminderej
- Department of Chemistry, College of Science, Qassim University, Buraidah 51452, Saudi Arabia; (F.A.); (F.A.); (S.G.); (B.H.); (A.E.A.E.A.)
| | - Siwar Ghannay
- Department of Chemistry, College of Science, Qassim University, Buraidah 51452, Saudi Arabia; (F.A.); (F.A.); (S.G.); (B.H.); (A.E.A.E.A.)
| | - Bechir Hammami
- Department of Chemistry, College of Science, Qassim University, Buraidah 51452, Saudi Arabia; (F.A.); (F.A.); (S.G.); (B.H.); (A.E.A.E.A.)
- Faculty of Sciences of Bizerte FSB, University of Carthage, Jarzouna 7021, Tunisia
| | - Abuzar E. A. E. Albadri
- Department of Chemistry, College of Science, Qassim University, Buraidah 51452, Saudi Arabia; (F.A.); (F.A.); (S.G.); (B.H.); (A.E.A.E.A.)
| | - Adel Kadri
- Department of Chemistry, Faculty of Science of Sfax, University of Sfax, B.P. 1171, Sfax 3000, Tunisia
- Faculty of Science and Arts in Baljurashi, Al-Baha University, P.O. Box 1988, Al-Baha 65527, Saudi Arabia
| | - Kaiss Aouadi
- Department of Chemistry, College of Science, Qassim University, Buraidah 51452, Saudi Arabia; (F.A.); (F.A.); (S.G.); (B.H.); (A.E.A.E.A.)
- Laboratory of Heterocyclic Chemistry, LR11ES39, Department of Chemistry, Faculty of Science of Monastir, University of Monastir, Avenue of the Environment, Monastir 5019, Tunisia
| |
Collapse
|
4
|
Tavares JO, Cotas J, Valado A, Pereira L. Algae Food Products as a Healthcare Solution. Mar Drugs 2023; 21:578. [PMID: 37999402 PMCID: PMC10672234 DOI: 10.3390/md21110578] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/14/2023] [Revised: 10/16/2023] [Accepted: 11/03/2023] [Indexed: 11/25/2023] Open
Abstract
Diseases such as obesity; cardiovascular diseases such as high blood pressure, myocardial infarction and stroke; digestive diseases such as celiac disease; certain types of cancer and osteoporosis are related to food. On the other hand, as the world's population increases, the ability of the current food production system to produce food consistently is at risk. As a result, intensive agriculture has contributed to climate change and a major environmental impact. Research is, therefore, needed to find new sustainable food sources. One of the most promising sources of sustainable food raw materials is macroalgae. Algae are crucial to solving this nutritional deficiency because they are abundant in bioactive substances that have been shown to combat diseases such as hyperglycemia, diabetes, obesity, metabolic disorders, neurodegenerative diseases and cardiovascular diseases. Examples of these substances include polysaccharides such as alginate, fucoidan, agar and carrageenan; proteins such as phycobiliproteins; carotenoids such as β-carotene and fucoxanthin; phenolic compounds; vitamins and minerals. Seaweed is already considered a nutraceutical food since it has higher protein values than legumes and soy and is, therefore, becoming increasingly common. On the other hand, compounds such as polysaccharides extracted from seaweed are already used in the food industry as thickening agents and stabilizers to improve the quality of the final product and to extend its shelf life; they have also demonstrated antidiabetic effects. Among the other bioactive compounds present in macroalgae, phenolic compounds, pigments, carotenoids and fatty acids stand out due to their different bioactive properties, such as antidiabetics, antimicrobials and antioxidants, which are important in the treatment or control of diseases such as diabetes, cholesterol, hyperglycemia and cardiovascular diseases. That said, there have already been some studies in which macroalgae (red, green and brown) have been incorporated into certain foods, but studies on gluten-free products are still scarce, as only the potential use of macroalgae for this type of product is considered. Considering the aforementioned issues, this review aims to analyze how macroalgae can be incorporated into foods or used as a food supplement, as well as to describe the bioactive compounds they contain, which have beneficial properties for human health. In this way, the potential of macroalgae-based products in eminent diseases, such as celiac disease, or in more common diseases, such as diabetes and cholesterol complications, can be seen.
Collapse
Affiliation(s)
- Joana O Tavares
- Department of Life Sciences, University of Coimbra, 3000-456 Coimbra, Portugal
| | - João Cotas
- Department of Life Sciences, University of Coimbra, 3000-456 Coimbra, Portugal
- MARE-Marine and Environmental Sciences Centre/ARNET-Aquatic Research Network, University of Coimbra, 3000-456 Coimbra, Portugal
| | - Ana Valado
- MARE-Marine and Environmental Sciences Centre/ARNET-Aquatic Research Network, University of Coimbra, 3000-456 Coimbra, Portugal
- Biomedical Laboratory Sciences, Coimbra Health School, Polytechnic Institute of Coimbra, Rua 5 de Outubro-SM Bispo, Apartado 7006, 3045-043 Coimbra, Portugal
| | - Leonel Pereira
- Department of Life Sciences, University of Coimbra, 3000-456 Coimbra, Portugal
- MARE-Marine and Environmental Sciences Centre/ARNET-Aquatic Research Network, University of Coimbra, 3000-456 Coimbra, Portugal
- Instituto do Ambiente Tecnologia e Vida, Faculdade de Ciências e Tecnologia, Rua Sílvio Lima, 3030-790 Coimbra, Portugal
| |
Collapse
|
5
|
Jiménez-Osorio AS, Carreón-Torres E, Correa-Solís E, Ángel-García J, Arias-Rico J, Jiménez-Garza O, Morales-Castillejos L, Díaz-Zuleta HA, Baltazar-Tellez RM, Sánchez-Padilla ML, Flores-Chávez OR, Estrada-Luna D. Inflammation and Oxidative Stress Induced by Obesity, Gestational Diabetes, and Preeclampsia in Pregnancy: Role of High-Density Lipoproteins as Vectors for Bioactive Compounds. Antioxidants (Basel) 2023; 12:1894. [PMID: 37891973 PMCID: PMC10604737 DOI: 10.3390/antiox12101894] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/06/2023] [Revised: 10/05/2023] [Accepted: 10/13/2023] [Indexed: 10/29/2023] Open
Abstract
Inflammation and oxidative stress are essential components in a myriad of pathogenic entities that lead to metabolic and chronic diseases. Moreover, inflammation in its different phases is necessary for the initiation and maintenance of a healthy pregnancy. Therefore, an equilibrium between a necessary/pathologic level of inflammation and oxidative stress during pregnancy is needed to avoid disease development. High-density lipoproteins (HDL) are important for a healthy pregnancy and a good neonatal outcome. Their role in fetal development during challenging situations is vital for maintaining the equilibrium. However, in certain conditions, such as obesity, diabetes, and other cardiovascular diseases, it has been observed that HDL loses its protective properties, becoming dysfunctional. Bioactive compounds have been widely studied as mediators of inflammation and oxidative stress in different diseases, but their mechanisms of action are still unknown. Nonetheless, these agents, which are obtained from functional foods, increase the concentration of HDL, TRC, and antioxidant activity. Therefore, this review first summarizes several mechanisms of HDL participation in the equilibrium between inflammation and oxidative stress. Second, it gives an insight into how HDL may act as a vector for bioactive compounds. Third, it describes the relationships between the inflammation process in pregnancy and HDL activity. Consequently, different databases were used, including MEDLINE, PubMed, and Scopus, where scientific articles published in the English language up to 2023 were identified.
Collapse
Affiliation(s)
- Angélica Saraí Jiménez-Osorio
- Área Académica de Enfermería, Instituto de Ciencias de la Salud, Universidad Autónoma del Estado Hida go, Circuito Ex Hacienda La Concepción S/N, Carretera Pachuca-Actopan, San Agustín Tlaxiaca 42160, Hidalgo, Mexico; (A.S.J.-O.); (J.Á.-G.); (J.A.-R.); (O.J.-G.); (L.M.-C.); (R.M.B.-T.); (M.L.S.-P.); (O.R.F.-C.)
| | - Elizabeth Carreón-Torres
- Department of Molecular Biology, Instituto Nacional de Cardiología “Ignacio Chávez”, Juan Badiano 1, Sección XVI, Tlalpan, Mexico City 14080, Mexico;
| | - Emmanuel Correa-Solís
- Instituto de Farmacobiología, Universidad de la Cañada, Carretera Teotitlán-San Antonio Nanahuatipán Km 1.7 s/n., Paraje Titlacuatitla, Teotitlán de Flores Magón 68540, Oaxaca, Mexico;
| | - Julieta Ángel-García
- Área Académica de Enfermería, Instituto de Ciencias de la Salud, Universidad Autónoma del Estado Hida go, Circuito Ex Hacienda La Concepción S/N, Carretera Pachuca-Actopan, San Agustín Tlaxiaca 42160, Hidalgo, Mexico; (A.S.J.-O.); (J.Á.-G.); (J.A.-R.); (O.J.-G.); (L.M.-C.); (R.M.B.-T.); (M.L.S.-P.); (O.R.F.-C.)
| | - José Arias-Rico
- Área Académica de Enfermería, Instituto de Ciencias de la Salud, Universidad Autónoma del Estado Hida go, Circuito Ex Hacienda La Concepción S/N, Carretera Pachuca-Actopan, San Agustín Tlaxiaca 42160, Hidalgo, Mexico; (A.S.J.-O.); (J.Á.-G.); (J.A.-R.); (O.J.-G.); (L.M.-C.); (R.M.B.-T.); (M.L.S.-P.); (O.R.F.-C.)
| | - Octavio Jiménez-Garza
- Área Académica de Enfermería, Instituto de Ciencias de la Salud, Universidad Autónoma del Estado Hida go, Circuito Ex Hacienda La Concepción S/N, Carretera Pachuca-Actopan, San Agustín Tlaxiaca 42160, Hidalgo, Mexico; (A.S.J.-O.); (J.Á.-G.); (J.A.-R.); (O.J.-G.); (L.M.-C.); (R.M.B.-T.); (M.L.S.-P.); (O.R.F.-C.)
| | - Lizbeth Morales-Castillejos
- Área Académica de Enfermería, Instituto de Ciencias de la Salud, Universidad Autónoma del Estado Hida go, Circuito Ex Hacienda La Concepción S/N, Carretera Pachuca-Actopan, San Agustín Tlaxiaca 42160, Hidalgo, Mexico; (A.S.J.-O.); (J.Á.-G.); (J.A.-R.); (O.J.-G.); (L.M.-C.); (R.M.B.-T.); (M.L.S.-P.); (O.R.F.-C.)
| | - Hugo Alexander Díaz-Zuleta
- Facultad de Ciencias de la Salud, Universidad de Ciencias Aplicadas y Ambientales, Cl. 222 #54-21, Bogotá 111166, Colombia;
| | - Rosa María Baltazar-Tellez
- Área Académica de Enfermería, Instituto de Ciencias de la Salud, Universidad Autónoma del Estado Hida go, Circuito Ex Hacienda La Concepción S/N, Carretera Pachuca-Actopan, San Agustín Tlaxiaca 42160, Hidalgo, Mexico; (A.S.J.-O.); (J.Á.-G.); (J.A.-R.); (O.J.-G.); (L.M.-C.); (R.M.B.-T.); (M.L.S.-P.); (O.R.F.-C.)
| | - María Luisa Sánchez-Padilla
- Área Académica de Enfermería, Instituto de Ciencias de la Salud, Universidad Autónoma del Estado Hida go, Circuito Ex Hacienda La Concepción S/N, Carretera Pachuca-Actopan, San Agustín Tlaxiaca 42160, Hidalgo, Mexico; (A.S.J.-O.); (J.Á.-G.); (J.A.-R.); (O.J.-G.); (L.M.-C.); (R.M.B.-T.); (M.L.S.-P.); (O.R.F.-C.)
| | - Olga Rocío Flores-Chávez
- Área Académica de Enfermería, Instituto de Ciencias de la Salud, Universidad Autónoma del Estado Hida go, Circuito Ex Hacienda La Concepción S/N, Carretera Pachuca-Actopan, San Agustín Tlaxiaca 42160, Hidalgo, Mexico; (A.S.J.-O.); (J.Á.-G.); (J.A.-R.); (O.J.-G.); (L.M.-C.); (R.M.B.-T.); (M.L.S.-P.); (O.R.F.-C.)
| | - Diego Estrada-Luna
- Área Académica de Enfermería, Instituto de Ciencias de la Salud, Universidad Autónoma del Estado Hida go, Circuito Ex Hacienda La Concepción S/N, Carretera Pachuca-Actopan, San Agustín Tlaxiaca 42160, Hidalgo, Mexico; (A.S.J.-O.); (J.Á.-G.); (J.A.-R.); (O.J.-G.); (L.M.-C.); (R.M.B.-T.); (M.L.S.-P.); (O.R.F.-C.)
| |
Collapse
|
6
|
Pereira L, Valado A. Algae-Derived Natural Products in Diabetes and Its Complications-Current Advances and Future Prospects. Life (Basel) 2023; 13:1831. [PMID: 37763235 PMCID: PMC10533039 DOI: 10.3390/life13091831] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2023] [Revised: 08/17/2023] [Accepted: 08/28/2023] [Indexed: 09/29/2023] Open
Abstract
Diabetes poses a significant global health challenge, necessitating innovative therapeutic strategies. Natural products and their derivatives have emerged as promising candidates for diabetes management due to their diverse compositions and pharmacological effects. Algae, in particular, have garnered attention for their potential as a source of bioactive compounds with anti-diabetic properties. This review offers a comprehensive overview of algae-derived natural products for diabetes management, highlighting recent developments and future prospects. It underscores the pivotal role of natural products in diabetes care and delves into the diversity of algae, their bioactive constituents, and underlying mechanisms of efficacy. Noteworthy algal derivatives with substantial potential are briefly elucidated, along with their specific contributions to addressing distinct aspects of diabetes. The challenges and limitations inherent in utilizing algae for therapeutic interventions are examined, accompanied by strategic recommendations for optimizing their effectiveness. By addressing these considerations, this review aims to chart a course for future research in refining algae-based approaches. Leveraging the multifaceted pharmacological activities and chemical components of algae holds significant promise in the pursuit of novel antidiabetic treatments. Through continued research and the fine-tuning of algae-based interventions, the global diabetes burden could be mitigated, ultimately leading to enhanced patient outcomes.
Collapse
Affiliation(s)
- Leonel Pereira
- Department of Life Sciences, University of Coimbra, Calçada Martim de Freitas, 3000-456 Coimbra, Portugal
- MARE-Marine and Environmental Sciences Centre/ARNET-Aquatic Research Network, University of Coimbra, 3000-456 Coimbra, Portugal;
| | - Ana Valado
- MARE-Marine and Environmental Sciences Centre/ARNET-Aquatic Research Network, University of Coimbra, 3000-456 Coimbra, Portugal;
- Biomedical Laboratory Sciences, Polytechnic Institute of Coimbra, Coimbra Health School, Rua 5 de Outubro-SM Bispo, Apartado 7006, 3045-043 Coimbra, Portugal
| |
Collapse
|
7
|
Dobrijević D, Pastor K, Nastić N, Özogul F, Krulj J, Kokić B, Bartkiene E, Rocha JM, Kojić J. Betaine as a Functional Ingredient: Metabolism, Health-Promoting Attributes, Food Sources, Applications and Analysis Methods. Molecules 2023; 28:4824. [PMID: 37375378 DOI: 10.3390/molecules28124824] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/19/2023] [Revised: 06/13/2023] [Accepted: 06/15/2023] [Indexed: 06/29/2023] Open
Abstract
Betaine is a non-essential amino acid with proven functional properties and underutilized potential. The most common dietary sources of betaine are beets, spinach, and whole grains. Whole grains-such as quinoa, wheat and oat brans, brown rice, barley, etc.-are generally considered rich sources of betaine. This valuable compound has gained popularity as an ingredient in novel and functional foods due to the demonstrated health benefits that it may provide. This review study will provide an overview of the various natural sources of betaine, including different types of food products, and explore the potential of betaine as an innovative functional ingredient. It will thoroughly discuss its metabolic pathways and physiology, disease-preventing and health-promoting properties, and further highlight the extraction procedures and detection methods in different matrices. In addition, gaps in the existing scientific literature will be emphasized.
Collapse
Affiliation(s)
- Dejan Dobrijević
- Faculty of Medicine Novi Sad, University of Novi Sad, 21000 Novi Sad, Serbia
- Institute for Children and Youth Health Care of Vojvodina, 21000 Novi Sad, Serbia
| | - Kristian Pastor
- Faculty of Technology Novi Sad, University of Novi Sad, 21000 Novi Sad, Serbia
| | - Nataša Nastić
- Faculty of Technology Novi Sad, University of Novi Sad, 21000 Novi Sad, Serbia
| | - Fatih Özogul
- Department of Seafood Processing Technology, Faculty of Fisheries, Cukurova University, 01330 Adana, Turkey
| | - Jelena Krulj
- Institute of Food Technology (FINS), University of Novi Sad, 21000 Novi Sad, Serbia
| | - Bojana Kokić
- Institute of Food Technology (FINS), University of Novi Sad, 21000 Novi Sad, Serbia
| | - Elena Bartkiene
- Department of Food Safety and Quality, Lithuanian University of Health Sciences, 44307 Kaunas, Lithuania
- Institute of Animal Rearing Technologies, Faculty of Animal Sciences, Lithuanian University of Health Sciences, Tilzes Str. 18, 44307 Kaunas, Lithuania
| | - João Miguel Rocha
- CBQF-Centro de Biotecnologia e Química Fina-Laboratório Associado, Escola Superior de Biotecnologia, Universidade Católica Portuguesa, Rua Diogo Botelho 1327, 4169-005 Porto, Portugal
- LEPABE-Laboratory for Process Engineering, Environment, Biotechnology and Energy, Faculty of Engineering, University of Porto, Rua Dr. Roberto Frias, s/n, 4200-465 Porto, Portugal
- ALiCE-Associate Laboratory in Chemical Engineering, Faculty of Engineering, University of Porto, Rua Dr. Roberto Frias, s/n, 4200-465 Porto, Portugal
| | - Jovana Kojić
- Institute of Food Technology (FINS), University of Novi Sad, 21000 Novi Sad, Serbia
| |
Collapse
|
8
|
Ağagündüz D, Icer MA, Yesildemir O, Koçak T, Kocyigit E, Capasso R. The roles of dietary lipids and lipidomics in gut-brain axis in type 2 diabetes mellitus. J Transl Med 2023; 21:240. [PMID: 37009872 PMCID: PMC10068184 DOI: 10.1186/s12967-023-04088-5] [Citation(s) in RCA: 12] [Impact Index Per Article: 12.0] [Reference Citation Analysis] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/20/2023] [Accepted: 03/25/2023] [Indexed: 04/04/2023] Open
Abstract
Type 2 diabetes mellitus (T2DM), one of the main types of Noncommunicable diseases (NCDs), is a systemic inflammatory disease characterized by dysfunctional pancreatic β-cells and/or peripheral insulin resistance, resulting in impaired glucose and lipid metabolism. Genetic, metabolic, multiple lifestyle, and sociodemographic factors are known as related to high T2DM risk. Dietary lipids and lipid metabolism are significant metabolic modulators in T2DM and T2DM-related complications. Besides, accumulated evidence suggests that altered gut microbiota which plays an important role in the metabolic health of the host contributes significantly to T2DM involving impaired or improved glucose and lipid metabolism. At this point, dietary lipids may affect host physiology and health via interaction with the gut microbiota. Besides, increasing evidence in the literature suggests that lipidomics as novel parameters detected with holistic analytical techniques have important roles in the pathogenesis and progression of T2DM, through various mechanisms of action including gut-brain axis modulation. A better understanding of the roles of some nutrients and lipidomics in T2DM through gut microbiota interactions will help develop new strategies for the prevention and treatment of T2DM. However, this issue has not yet been entirely discussed in the literature. The present review provides up-to-date knowledge on the roles of dietary lipids and lipidomics in gut-brain axis in T2DM and some nutritional strategies in T2DM considering lipids- lipidomics and gut microbiota interactions are given.
Collapse
Affiliation(s)
- Duygu Ağagündüz
- Department of Nutrition and Dietetics, Faculty of Health Sciences, Gazi University, 06490, Ankara, Turkey.
| | - Mehmet Arif Icer
- Department of Nutrition and Dietetics, Faculty of Health Sciences, Amasya University, 05100, Amasya, Turkey
| | - Ozge Yesildemir
- Department of Nutrition and Dietetics, Faculty of Health Sciences, Bursa Uludag University, 16059, Bursa, Turkey
| | - Tevfik Koçak
- Department of Nutrition and Dietetics, Faculty of Health Sciences, Gazi University, 06490, Ankara, Turkey
| | - Emine Kocyigit
- Department of Nutrition and Dietetics, Faculty of Health Sciences, Ordu University, 52200, Ordu, Turkey
| | - Raffaele Capasso
- Department of Agricultural Sciences, University of Naples Federico II, Portici, 80055, Naples, Italy.
| |
Collapse
|
9
|
Abo-Shady AM, Gheda SF, Ismail GA, Cotas J, Pereira L, Abdel-Karim OH. Antioxidant and Antidiabetic Activity of Algae. Life (Basel) 2023; 13:life13020460. [PMID: 36836817 PMCID: PMC9964347 DOI: 10.3390/life13020460] [Citation(s) in RCA: 5] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2022] [Revised: 02/02/2023] [Accepted: 02/03/2023] [Indexed: 02/10/2023] Open
Abstract
Currently, algae arouse a growing interest in the pharmaceutical and cosmetic area due to the fact that they have a great diversity of bioactive compounds with the potential for pharmacological and nutraceutical applications. Due to lifestyle modifications brought on by rapid urbanization, diabetes mellitus, a metabolic illness, is the third largest cause of death globally. The hunt for an efficient natural-based antidiabetic therapy is crucial to battling diabetes and the associated consequences due to the unfavorable side effects of currently available antidiabetic medications. Finding the possible advantages of algae for the control of diabetes is crucial for the creation of natural drugs. Many of algae's metabolic processes produce bioactive secondary metabolites, which give algae their diverse chemical and biological features. Numerous studies have demonstrated the antioxidant and antidiabetic benefits of algae, mostly by blocking carbohydrate hydrolyzing enzyme activity, such as α-amylase and α-glucosidase. Additionally, bioactive components from algae can lessen diabetic symptoms in vivo. Therefore, the current review concentrates on the role of various secondary bioactive substances found naturally in algae and their potential as antioxidants and antidiabetic materials, as well as the urgent need to apply these substances in the pharmaceutical industry.
Collapse
Affiliation(s)
| | - Saly Farouk Gheda
- Botany Department, Faculty of Science, Tanta University, Tanta 31527, Egypt
| | - Gehan Ahmed Ismail
- Botany Department, Faculty of Science, Tanta University, Tanta 31527, Egypt
| | - João Cotas
- MARE—Marine and Environmental Sciences Centre/ARNET—Aquatic Research Network, Department of Life Sciences, University of Coimbra, Calçada Martim de Freitas, 3000-456 Coimbra, Portugal
| | - Leonel Pereira
- MARE—Marine and Environmental Sciences Centre/ARNET—Aquatic Research Network, Department of Life Sciences, University of Coimbra, Calçada Martim de Freitas, 3000-456 Coimbra, Portugal
- Correspondence: (L.P.); or (O.H.A.-K.)
| | - Omnia Hamdy Abdel-Karim
- Botany Department, Faculty of Science, Tanta University, Tanta 31527, Egypt
- Bioprocess Engineering & AlgaePARC, Wageningen University and Research, 6700 AA Wageningen, The Netherlands
- Correspondence: (L.P.); or (O.H.A.-K.)
| |
Collapse
|
10
|
Rizzo G, Baroni L, Lombardo M. Promising Sources of Plant-Derived Polyunsaturated Fatty Acids: A Narrative Review. INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH 2023; 20:ijerph20031683. [PMID: 36767052 PMCID: PMC9914036 DOI: 10.3390/ijerph20031683] [Citation(s) in RCA: 8] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/27/2022] [Revised: 01/11/2023] [Accepted: 01/15/2023] [Indexed: 06/01/2023]
Abstract
(1) Background: Polyunsaturated fatty acids (PUFAs) are known for their ability to protect against numerous metabolic disorders. The consumption of oily fish is the main source of PUFAs in human nutrition and is commonly used for supplement production. However, seafood is an overexploited source that cannot be guaranteed to cover the global demands. Furthermore, it is not consumed by everyone for ecological, economic, ethical, geographical and taste reasons. The growing demand for natural dietary sources of PUFAs suggests that current nutritional sources are insufficient to meet global needs, and less and less will be. Therefore, it is crucial to find sustainable sources that are acceptable to all, meeting the world population's needs. (2) Scope: This review aims to evaluate the recent evidence about alternative plant sources of essential fatty acids, focusing on long-chain omega-3 (n-3) PUFAs. (3) Method: A structured search was performed on the PubMed search engine to select available human data from interventional studies using omega-3 fatty acids of non-animal origin. (4) Results: Several promising sources have emerged from the literature, such as algae, microorganisms, plants rich in stearidonic acid and GM plants. However, the costs, acceptance and adequate formulation deserve further investigation.
Collapse
Affiliation(s)
- Gianluca Rizzo
- Independent Researcher, Via Venezuela 66, 98121 Messina, Italy
| | - Luciana Baroni
- Scientific Society for Vegetarian Nutrition, 30171 Venice, Italy
| | - Mauro Lombardo
- Department of Human Sciences and Promotion of the Quality of Life, San Raffaele Open University, 00166 Rome, Italy
| |
Collapse
|
11
|
Lee S, Lee EJ, Lee GM, Yun JH, Yoo W. Inhibitory effect of fucoidan on TNF-α-induced inflammation in human retinal pigment epithelium cells. Front Nutr 2023; 10:1162934. [PMID: 37125026 PMCID: PMC10130517 DOI: 10.3389/fnut.2023.1162934] [Citation(s) in RCA: 4] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/10/2023] [Accepted: 03/27/2023] [Indexed: 05/02/2023] Open
Abstract
Sargassum horneri (S. horneri) is a brown seaweed that contains a fucose-rich sulfated polysaccharide called fucoidan and is known to possess beneficial bioactivities, such as anti-inflammatory, antiviral, antioxidative, and antitumoral effects. This study aimed to determine the anti-inflammatory effects of AB_SH (hydrothermal extracts from S. horneri) and its bioactive compound (fucoidan) against tumor necrosis factor alpha (TNF-α)-induced inflammation in human retinal pigment epithelial (RPE) cells. AB_SH did not exhibit any cytotoxicity, and it decreased the mRNA expression of interleukin (IL)-6 and IL-8 and the production of the cytokines IL-6 and TNF-α. It also suppressed the expression levels of phosphorylated nuclear factor kappa B (NF-κB) and mitogen-activated protein kinases (MAPKs), including c-Jun amino-terminal kinases (JNK), p38 protein kinases (p38), and extracellular signal-regulated kinase (ERK) proteins, suggesting that AB_SH inhibits activation of the NF-kB/MAPK signaling pathway. Since fucoidan was identified in the composition analysis of AB_SH, it was additionally shown to be required for its anti-inflammatory effects in TNF-α-stimulated human RPE cells. In line with the AB_SH results, fucoidan reduced the mRNA levels of IL-6, IL-1ß, and IL-8 and production of the cytokines IL-6, TNF-α, and IL-8 through the downregulation of the NF-kB/MAPK signaling pathway in a dose-dependent manner. Collectively, the ability of AB_SH from S. horneri hydrothermal extracts to reduce inflammation indicates that it may be a good functional ingredient for managing ocular disorders.
Collapse
Affiliation(s)
- Sol Lee
- AceBiome Inc., Seoul, Republic of Korea
- R&D Center, AceBiome Inc., Daejeon, Republic of Korea
| | - Eun Jeoung Lee
- AceBiome Inc., Seoul, Republic of Korea
- R&D Center, AceBiome Inc., Daejeon, Republic of Korea
| | - Gyu Min Lee
- AceBiome Inc., Seoul, Republic of Korea
- R&D Center, AceBiome Inc., Daejeon, Republic of Korea
| | - Ji-Hyun Yun
- AceBiome Inc., Seoul, Republic of Korea
- R&D Center, AceBiome Inc., Daejeon, Republic of Korea
| | - Wonbeak Yoo
- AceBiome Inc., Seoul, Republic of Korea
- R&D Center, AceBiome Inc., Daejeon, Republic of Korea
- *Correspondence: Wonbeak Yoo,
| |
Collapse
|
12
|
Lee KH, Jang YJ, Hwang WS, Kwon KS, Lee WY, Kim J, Kim SP, Friedman M. Edible algae (Ecklonia cava) bioprocessed with mycelia of shiitake (Lentinula edodes) mushrooms in liquid culture and its isolated fractions protect mice against allergic asthma. BMC Complement Med Ther 2022; 22:242. [PMID: 36115955 PMCID: PMC9482293 DOI: 10.1186/s12906-022-03705-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/05/2022] [Accepted: 08/01/2022] [Indexed: 12/03/2022] Open
Abstract
BACKGROUND Ecklonia cava is an edible marine brown alga harvested from the ocean that is widely consumed in Asian countries as a health-promoting medicinal food The objective of the present study is to evaluate the anti-asthma mechanism of a new functional food produced by bioprocessing edible algae Ecklonia cava and shiitake Lentinula edodes mushroom mycelia and isolated fractions. METHODS We used as series of methods, including high performance liquid chromatography, gas chromatography, cell assays, and an in vivo mouse assay to evaluate the asthma-inhibitory effect of Ecklonia cava bioprocessed (fermented) with Lentinula edodes shiitake mushroom mycelium and its isolated fractions in mast cells and in orally fed mice. RESULTS The treatments inhibited the degranulation of RBL-2H3 cells and immunoglobulin E (IgE) production, suggesting anti-asthma effects in vitro. The in vitro anti-asthma effects in cells were confirmed in mice following the induction of asthma by alumina and chicken egg ovalbumin (OVA). Oral administration of the bioprocessed Ecklonia cava and purified fractions suppressed the induction of asthma and was accompanied by the inhibition of inflammation- and immune-related substances, including eotaxin; thymic stromal lymphopoietin (TSLP); OVA-specific IgE; leukotriene C4 (LTC4); prostaglandin D2 (PGD2); and vascular cell adhesion molecule-1 (VCAM-1) in bronchoalveolar lavage fluid (BALF) and other fluids and organs. Th2 cytokines were reduced and Th1 cytokines were restored in serum, suggesting the asthma-induced inhibitory effect is regulated by the balance of the Th1/Th2 immune response. Serum levels of IL-10, a regulatory T cell (Treg) cytokine, were increased, further favoring reduced inflammation. Histology of lung tissues revealed that the treatment also reversed the thickening of the airway wall and the contraction and infiltration of bronchial and blood vessels and perialveolar inflammatory cells. The bioprocessed Ecklonia cava/mushroom mycelia new functional food showed the highest inhibition as compared with commercial algae and the fractions isolated from the bioprocessed product. CONCLUSIONS The in vitro cell and in vivo mouse assays demonstrate the potential value of the new bioprocessed formulation as an anti-inflammatory and anti-allergic combination of natural compounds against allergic asthma and might also ameliorate allergic manifestations of foods, drugs, and viral infections.
Collapse
Affiliation(s)
| | - Yeo Jin Jang
- STR Biotech Co., Ltd., Chuncheon, Republic of Korea
- Present address: Herbal Medicine Research Division, National Institute of Food & Drug Safety Evaluation, Cheongju, Republic of Korea
| | | | - Ki Sun Kwon
- STR Biotech Co., Ltd., Chuncheon, Republic of Korea
| | | | - Jeanman Kim
- STR Biotech Co., Ltd., Chuncheon, Republic of Korea
| | - Sung Phil Kim
- STR Biotech Co., Ltd., Chuncheon, Republic of Korea.
| | - Mendel Friedman
- U.S. Department of Agriculture, Western Regional Research Center, Agricultural Research Services, Albany, CA, USA.
| |
Collapse
|
13
|
A Narrative Review of Alternative Protein Sources: Highlights on Meat, Fish, Egg and Dairy Analogues. Foods 2022; 11:foods11142053. [PMID: 35885293 PMCID: PMC9316106 DOI: 10.3390/foods11142053] [Citation(s) in RCA: 12] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2022] [Revised: 07/03/2022] [Accepted: 07/04/2022] [Indexed: 11/17/2022] Open
Abstract
The research and development of alternatives to meat (including fish) and dairy products for human consumption have been increasing in recent years. In the context of these alternatives, there is a diversity of products such as tofu, tempeh, seitan, pulses, algae, seeds, nuts and insects. Apart from these, some products require new technical processes such as needed by milk drink alternatives, mycoprotein and meat, cheese and fish analogues. The aim of these analogues is to mimic the physical and organoleptic properties of animal origin products through fibrous composition and mix of ingredients from vegetable sources using adequate technology, which allow providing similar texture and flavor. Using a narrative approach to review literature, the objectives of this paper are to systematize the arguments supporting the adoption of meat, eggs and dairy alternatives, to identify the diversity of alternatives to these products on the market, including the related technological processes, and to project the challenges that the food industry may face soon. From a total of 302 scientific papers identified in databases, 186 papers were considered. More research papers on products associated with alternatives to milk were found. Nevertheless, there are products that need more research as analogues to meat and dairy products. A general scheme that brings together the main reasons, resources and challenges that the food industry faces in this promising area of alternatives to meat and dairy products is presented.
Collapse
|
14
|
Wang M, Yang F, Yan X, Chao X, Zhang W, Yuan C, Zeng Q. Anti-diabetic effect of banana peel dietary fibers on type 2 diabetic mellitus mice induced by streptozotocin and high-sugar and high-fat diet. J Food Biochem 2022; 46:e14275. [PMID: 35765856 DOI: 10.1111/jfbc.14275] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2022] [Revised: 04/16/2022] [Accepted: 05/28/2022] [Indexed: 11/30/2022]
Abstract
We used a high-fat diet (HFD) and streptozotocin (STZ) to induce type 2 diabetic mellitus (T2DM) mice and evaluated the effect of banana peel dietary fibers (BP-DFs) as potential hypoglycemic agents. After 5 weeks of intervention with banana peel dietary fibers (BP-DFs), food intake was reduced, body weight was increased, blood lipids and glucose were reduced, fasting insulin and GLP-1 levels were increased, and liver and pancreatic tissue damage was reduced. Banana peel soluble dietary fiber (BP-SDF) has the most significant effect. The results of fecal microbiota analysis showed that BP-DFs could ameliorates gut microbiome dysbiosis, and all three types of dietary fibers have obvious effects. The results of fecal short-chain fatty acids (SCFAs) showed that the content of fecal SCFAs was increased after BP-DFs dietary intervention, and BP-SDF had the most obvious effect. RT-PCR experiment results show that BP-DFs can up-regulate the mRNA expression levels of PI3K, AKT, IRS-1, and FOXO1 in the liver of diabetic mice, which indicates that BD-DFs may play a role in improving insulin resistance and insulin signal transduction via the IRS/PI3K/AKT pathway, improving insulin resistance and insulin signal transduction. Our research may be extended to BP-DFs, especially BP-SDF, as the basis for potential dietary intervention to prevent or treat type 2 diabetic mellitus. This work supports future research studies of the anti-diabetic properties of BP-SDF in humans. PRACTICAL APPLICATIONS: Diabetes can lead to a variety of complications that have a huge impact on health. Dietary fiber may help in lowering blood sugar. Our experimental results showed that banana peel dietary fibers have the effect of reducing food intake, blood sugar, improving liver and pancreas function, increasing the abundance of intestinal flora, and improving the IRS/PI3K/AKT pathway in T2DM mice. Therefore, this study could provide a theoretical basis for the development of functional foods with banana peel dietary fiber.
Collapse
Affiliation(s)
- Mengyang Wang
- Engineering Research Center of Bio-Process, Ministry of Education, Hefei University of Technology, Hefei, Anhui, PR China.,School of Food and Biological Engineering, Hefei University of Technology, Hefei, Anhui, PR China
| | - Fan Yang
- Engineering Research Center of Bio-Process, Ministry of Education, Hefei University of Technology, Hefei, Anhui, PR China.,School of Food and Biological Engineering, Hefei University of Technology, Hefei, Anhui, PR China
| | - Xiang Yan
- Engineering Research Center of Bio-Process, Ministry of Education, Hefei University of Technology, Hefei, Anhui, PR China.,School of Food and Biological Engineering, Hefei University of Technology, Hefei, Anhui, PR China
| | - Xinyu Chao
- Engineering Research Center of Bio-Process, Ministry of Education, Hefei University of Technology, Hefei, Anhui, PR China.,School of Food and Biological Engineering, Hefei University of Technology, Hefei, Anhui, PR China
| | - Wencheng Zhang
- Engineering Research Center of Bio-Process, Ministry of Education, Hefei University of Technology, Hefei, Anhui, PR China.,School of Food and Biological Engineering, Hefei University of Technology, Hefei, Anhui, PR China
| | - Chuanxun Yuan
- Engineering Research Center of Bio-Process, Ministry of Education, Hefei University of Technology, Hefei, Anhui, PR China.,School of Food and Biological Engineering, Hefei University of Technology, Hefei, Anhui, PR China
| | - Qingmei Zeng
- Engineering Research Center of Bio-Process, Ministry of Education, Hefei University of Technology, Hefei, Anhui, PR China.,School of Food and Biological Engineering, Hefei University of Technology, Hefei, Anhui, PR China
| |
Collapse
|
15
|
Tresserra-Rimbau A, Castro-Barquero S, Becerra-Tomás N, Babio N, Martínez-González MÁ, Corella D, Fitó M, Romaguera D, Vioque J, Alonso-Gomez AM, Wärnberg J, Martínez JA, Serra-Majem L, Estruch R, Tinahones FJ, Lapetra J, Pintó X, Tur JA, López-Miranda J, Cano-Ibáñez N, Delgado-Rodríguez M, Matía-Martín P, Daimiel L, Martín Sánchez V, Vidal J, Vázquez C, Ros E, Basterra FJ, Fernández de la Puente M, Asensio EM, Castañer O, Bullón-Vela V, Tojal-Sierra L, Gómez-Gracia E, Cases-Pérez E, Konieczna J, García-Ríos A, Casañas-Quintana T, Bernal-Lopez MR, Santos-Lozano JM, Esteve-Luque V, Bouzas C, Vázquez-Ruiz Z, Palau-Galindo A, Barragan R, López Grau M, Razquín C, Goicolea-Güemez L, Toledo E, Vergaz MV, Lamuela-Raventós RM, Salas-Salvadó J. Adopting a High-Polyphenolic Diet Is Associated with an Improved Glucose Profile: Prospective Analysis within the PREDIMED-Plus Trial. Antioxidants (Basel) 2022; 11:antiox11020316. [PMID: 35204199 PMCID: PMC8868059 DOI: 10.3390/antiox11020316] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2022] [Revised: 01/30/2022] [Accepted: 02/01/2022] [Indexed: 02/05/2023] Open
Abstract
Previous studies suggested that dietary polyphenols could reduce the incidence and complications of type-2 diabetes (T2D); although the evidence is still limited and inconsistent. This work analyzes whether changing to a diet with a higher polyphenolic content is associated with an improved glucose profile. At baseline, and at 1 year of follow-up visits, 5921 participants (mean age 65.0 ± 4.9, 48.2% women) who had overweight/obesity and metabolic syndrome filled out a validated 143-item semi-quantitative food frequency questionnaire (FFQ), from which polyphenol intakes were calculated. Energy-adjusted total polyphenols and subclasses were categorized in tertiles of changes. Linear mixed-effect models with random intercepts (the recruitment centers) were used to assess associations between changes in polyphenol subclasses intake and 1-year plasma glucose or glycosylated hemoglobin (HbA1c) levels. Increments in total polyphenol intake and some classes were inversely associated with better glucose levels and HbA1c after one year of follow-up. These associations were modified when the analyses were run considering diabetes status separately. To our knowledge, this is the first study to assess the relationship between changes in the intake of all polyphenolic groups and T2D-related parameters in a senior population with T2D or at high-risk of developing T2D.
Collapse
Affiliation(s)
- Anna Tresserra-Rimbau
- Department of Nutrition, Food Science and Gastronomy, XIA, School of Pharmacy and Food Sciences, INSA, University of Barcelona, 08921 Barcelona, Spain;
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Correspondence:
| | - Sara Castro-Barquero
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Department of Internal Medicine, Institut d’Investigacions Biomèdiques August Pi Sunyer (IDIBAPS), Hospital Clinic, University of Barcelona, 08036 Barcelona, Spain
| | - Nerea Becerra-Tomás
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London W2 1PG, UK
- Unitat de Nutrició, Departament de Bioquímica i Biotecnologia, Universitat Rovira i Virgili, 43204 Reus, Spain;
| | - Nancy Babio
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Unitat de Nutrició, Departament de Bioquímica i Biotecnologia, Universitat Rovira i Virgili, 43204 Reus, Spain;
- Nutrition Unit, University Hospital of Sant Joan de Reus, 43204 Reus, Spain
- Institut d’Investigació Sanitària Pere Virgili (IISPV), 43204 Reus, Spain
| | - Miguel Ángel Martínez-González
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Department of Preventive Medicine and Public Health, University of Navarra, IDISNA, 31008 Pamplona, Spain
- Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA
| | - Dolores Corella
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Department of Preventive Medicine, University of Valencia, 46010 Valencia, Spain
| | - Montserrat Fitó
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Unit of Cardiovascular Risk and Nutrition, Institut Hospital del Mar de Investigaciones Médicas Municipal d’Investigació Médica (IMIM), 08007 Barcelona, Spain
| | - Dora Romaguera
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Research Group on Nutritional Epidemiology & Cardiovascular Physiopathology (NUTRECOR), Health Research Institute of the Balearic Islands (IdISBa), 07120 Palma de Mallorca, Spain
| | - Jesús Vioque
- CIBER de Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Carlos III, 28029 Madrid, Spain; (J.V.); (N.C.-I.); (M.D.-R.); (V.M.S.)
- Alicante Institute for Health and Biomedical Research, University Miguel Hernandez (ISABIAL-UMH), 03010 Alicante, Spain
| | - Angel M. Alonso-Gomez
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Bioaraba Health Research Institute, Osakidetza Basque Health Service, Araba University Hospital, University of the Basque Country UPV/EHU, 01009 Vitoria-Gasteiz, Spain
| | - Julia Wärnberg
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Department of Nursing, Institute of Biomedical Research in Málaga (IBIMA), University of Málaga, 29010 Malaga, Spain
| | - José Alfredo Martínez
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Department of Nutrition, Food Sciences, and Physiology, Center for Nutrition Research, University of Navarra, 31008 Pamplona, Spain;
- Cardiometabolic Nutrition Group, IMDEA Food, CEI UAM + CSIC, 28049 Madrid, Spain
| | - Luís Serra-Majem
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Research Institute of Biomedical and Health Sciences (IUIBS), University of Las Palmas de Gran Canaria & Centro Hospitalario Universitario Insular Materno Infantil (CHUIMI), Canarian Health Service, 35016 Las Palmas de Gran Canaria, Spain
| | - Ramon Estruch
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Department of Internal Medicine, Institut d’Investigacions Biomèdiques August Pi Sunyer (IDIBAPS), Hospital Clinic, University of Barcelona, 08036 Barcelona, Spain
| | - Francisco J. Tinahones
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Department of Internal Medicine, Regional University Hospital of Malaga, Instituto de Investigación Biomédica de Malaga (IBIMA), University of Malaga, 29010 Malaga, Spain
| | - José Lapetra
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Department of Family Medicine, Research Unit, Distrito Sanitario Atención Primaria Sevilla, 41010 Sevilla, Spain
| | - Xavier Pintó
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Lipids and Vascular Risk Unit, Internal Medicine, Hospital Universitario de Bellvitge, 08908 Hospitalet de Llobregat, Spain;
| | - Josep A. Tur
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Research Group on Community Nutrition & Oxidative Stress, University of Balearic Islands-IUNICS, 07122 Palma de Mallorca, Spain
| | - José López-Miranda
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Department of Internal Medicine, Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, 14004 Cordoba, Spain
| | - Naomi Cano-Ibáñez
- CIBER de Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Carlos III, 28029 Madrid, Spain; (J.V.); (N.C.-I.); (M.D.-R.); (V.M.S.)
- Department of Preventive Medicine and Public Health, University of Granada, 18016 Granada, Spain
- Instituto de Investigación Biosanitaria, Complejo Hospitales Universitarios de Granada, Universidad de Granada, 18016 Granada, Spain
| | - Miguel Delgado-Rodríguez
- CIBER de Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Carlos III, 28029 Madrid, Spain; (J.V.); (N.C.-I.); (M.D.-R.); (V.M.S.)
- Division of Preventive Medicine, Faculty of Medicine, University of Jaén, 23071 Jaen, Spain
| | - Pilar Matía-Martín
- Department of Endocrinology and Nutrition, Instituto de Investigación Sanitaria Hospital Clínico San Carlos (IdISSC), 28040 Madrid, Spain;
| | - Lidia Daimiel
- Nutritional Control of the Epigenome Group, Precision Nutrition and Obesity Program, IMDEA Food, CEI UAM + CSIC, 28029 Madrid, Spain;
| | - Vicente Martín Sánchez
- CIBER de Epidemiología y Salud Pública (CIBERESP), Instituto de Salud Carlos III, 28029 Madrid, Spain; (J.V.); (N.C.-I.); (M.D.-R.); (V.M.S.)
- Institute of Biomedicine (IBIOMED), University of León, 24071 Leon, Spain
| | - Josep Vidal
- CIBER Diabetes y Enfermedades Metabólicas (CIBERDEM), Instituto de Salud Carlos III (ISCIII), 28029 Madrid, Spain;
- Department of Endocrinology, Institut d’Investigacions Biomédiques August Pi Sunyer (IDIBAPS), Hospital Clinic, University of Barcelona, 08036 Barcelona, Spain
| | - Clotilde Vázquez
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Department of Endocrinology and Nutrition, Hospital Fundación Jimenez Díaz, Instituto de Investigaciones Biomédicas IISFJD, University Autonoma, 28040 Madrid, Spain
| | - Emili Ros
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Lipid Clinic, Department of Endocrinology and Nutrition, Institut d’Investigacions Biomèdiques August Pi Sunyer (IDIBAPS), Hospital Clínic, 08036 Barcelona, Spain
| | - Francisco Javier Basterra
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Department of Preventive Medicine and Public Health, University of Navarra, IDISNA, 31008 Pamplona, Spain
| | - María Fernández de la Puente
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Unitat de Nutrició, Departament de Bioquímica i Biotecnologia, Universitat Rovira i Virgili, 43204 Reus, Spain;
- Nutrition Unit, University Hospital of Sant Joan de Reus, 43204 Reus, Spain
| | - Eva M. Asensio
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Department of Preventive Medicine, University of Valencia, 46010 Valencia, Spain
| | - Olga Castañer
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Unit of Cardiovascular Risk and Nutrition, Institut Hospital del Mar de Investigaciones Médicas Municipal d’Investigació Médica (IMIM), 08007 Barcelona, Spain
| | - Vanessa Bullón-Vela
- Department of Nutrition, Food Sciences, and Physiology, Center for Nutrition Research, University of Navarra, 31008 Pamplona, Spain;
| | - Lucas Tojal-Sierra
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Bioaraba Health Research Institute, Osakidetza Basque Health Service, Araba University Hospital, University of the Basque Country UPV/EHU, 01009 Vitoria-Gasteiz, Spain
| | - Enrique Gómez-Gracia
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Department of Preventive Medicine and Public Health, Instituto de Investigación Biomédica de Málaga-IBIMA, School of Medicine, University of Málaga, 29071 Malaga, Spain
| | | | - Jadwiga Konieczna
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Research Group on Nutritional Epidemiology & Cardiovascular Physiopathology (NUTRECOR), Health Research Institute of the Balearic Islands (IdISBa), 07120 Palma de Mallorca, Spain
| | - Antonio García-Ríos
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Department of Internal Medicine, Maimonides Biomedical Research Institute of Cordoba (IMIBIC), Reina Sofia University Hospital, University of Cordoba, 14004 Cordoba, Spain
| | - Tamara Casañas-Quintana
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Research Institute of Biomedical and Health Sciences (IUIBS), University of Las Palmas de Gran Canaria & Centro Hospitalario Universitario Insular Materno Infantil (CHUIMI), Canarian Health Service, 35016 Las Palmas de Gran Canaria, Spain
| | - María Rosa Bernal-Lopez
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Department of Internal Medicine, Regional University Hospital of Malaga, Instituto de Investigación Biomédica de Malaga (IBIMA), University of Malaga, 29010 Malaga, Spain
| | - José Manuel Santos-Lozano
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Department of Family Medicine, Research Unit, Distrito Sanitario Atención Primaria Sevilla, 41010 Sevilla, Spain
| | - Virginia Esteve-Luque
- Lipids and Vascular Risk Unit, Internal Medicine, Hospital Universitario de Bellvitge, 08908 Hospitalet de Llobregat, Spain;
| | - Cristina Bouzas
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Research Group on Community Nutrition & Oxidative Stress, University of Balearic Islands-IUNICS, 07122 Palma de Mallorca, Spain
| | - Zenaida Vázquez-Ruiz
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Department of Preventive Medicine and Public Health, University of Navarra, IDISNA, 31008 Pamplona, Spain
| | - Antoni Palau-Galindo
- Unitat de Nutrició, Departament de Bioquímica i Biotecnologia, Universitat Rovira i Virgili, 43204 Reus, Spain;
- ABS Reus V. Centre d’Assistència Primària Marià Fortuny, SAGESSA, 43205 Reus, Spain
| | - Rocio Barragan
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Department of Preventive Medicine, University of Valencia, 46010 Valencia, Spain
| | - Mercè López Grau
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Unit of Cardiovascular Risk and Nutrition, Institut Hospital del Mar de Investigaciones Médicas Municipal d’Investigació Médica (IMIM), 08007 Barcelona, Spain
| | - Cristina Razquín
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Department of Nutrition, Food Sciences, and Physiology, Center for Nutrition Research, University of Navarra, 31008 Pamplona, Spain;
- Cardiometabolic Nutrition Group, IMDEA Food, CEI UAM + CSIC, 28049 Madrid, Spain
| | - Leire Goicolea-Güemez
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Bioaraba Health Research Institute, Osakidetza Basque Health Service, Araba University Hospital, University of the Basque Country UPV/EHU, 01009 Vitoria-Gasteiz, Spain
| | - Estefanía Toledo
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Department of Preventive Medicine and Public Health, University of Navarra, IDISNA, 31008 Pamplona, Spain
- Department of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA
| | - Manel Vila Vergaz
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Unit of Cardiovascular Risk and Nutrition, Institut Hospital del Mar de Investigaciones Médicas Municipal d’Investigació Médica (IMIM), 08007 Barcelona, Spain
| | - Rosa M. Lamuela-Raventós
- Department of Nutrition, Food Science and Gastronomy, XIA, School of Pharmacy and Food Sciences, INSA, University of Barcelona, 08921 Barcelona, Spain;
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
| | - Jordi Salas-Salvadó
- Centro de Investigación Biomédica en Red Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), Institute of Health Carlos III, 28029 Madrid, Spain; (S.C.-B.); (N.B.-T.); (N.B.); (M.Á.M.-G.); (D.C.); (M.F.); (D.R.); (A.M.A.-G.); (J.W.); (J.A.M.); (L.S.-M.); (R.E.); (F.J.T.); (J.L.); (X.P.); (J.A.T.); (J.L.-M.); (C.V.); (E.R.); (F.J.B.); (M.F.d.l.P.); (E.M.A.); (O.C.); (L.T.-S.); (E.G.-G.); (J.K.); (A.G.-R.); (T.C.-Q.); (M.R.B.-L.); (J.M.S.-L.); (C.B.); (Z.V.-R.); (R.B.); (M.L.G.); (C.R.); (L.G.-G.); (E.T.); (M.V.V.); (J.S.-S.)
- Unitat de Nutrició, Departament de Bioquímica i Biotecnologia, Universitat Rovira i Virgili, 43204 Reus, Spain;
- Nutrition Unit, University Hospital of Sant Joan de Reus, 43204 Reus, Spain
- Institut d’Investigació Sanitària Pere Virgili (IISPV), 43204 Reus, Spain
| |
Collapse
|
16
|
Seaweed-Derived Proteins and Peptides: Promising Marine Bioactives. Antioxidants (Basel) 2022; 11:antiox11010176. [PMID: 35052680 PMCID: PMC8773382 DOI: 10.3390/antiox11010176] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2021] [Revised: 01/13/2022] [Accepted: 01/14/2022] [Indexed: 12/29/2022] Open
Abstract
Seaweeds are a typical food of East-Asian cuisine, to which are alleged several beneficial health effects have been attributed. Their availability and their nutritional and chemical composition have favored the increase in its consumption worldwide, as well as a focus of research due to their bioactive properties. In this regard, seaweed proteins are nutritionally valuable and comprise several specific enzymes, glycoproteins, cell wall-attached proteins, red algae phycobiliproteins, lectins, peptides, or mycosporine-like amino acids. This great extent of molecules has been reported to exert significant antioxidant, antimicrobial, anti-inflammatory, antihypertensive, antidiabetic, or antitumoral properties. Hence, knowledge on algae proteins and derived compounds have gained special interest for the potential nutraceutical, cosmetic or pharmaceutical industries based on these bioactivities. Although several molecular mechanisms of action on how these proteins and peptides exert biological activities have been described, many gaps in knowledge still need to be filled. Updating the current knowledge related to seaweed proteins and peptides is of interest to further asses their potential health benefits. This review addresses the characteristics of seaweed protein and protein-derived molecules, their natural occurrence, their studied bioactive properties, and their described potential mechanisms of action.
Collapse
|
17
|
Durazzo A, Lucarini M, Santini A. Plants and Diabetes: Description, Role, Comprehension and Exploitation. Int J Mol Sci 2021; 22:3938. [PMID: 33920409 PMCID: PMC8070195 DOI: 10.3390/ijms22083938] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/06/2021] [Accepted: 04/07/2021] [Indexed: 12/17/2022] Open
Abstract
Many plants have been known for centuries to have medicinal importance with potential beneficial effects on health. Phytotherapeutic compounds are well known to play a globally significant role, in particular in the management and treatment of various chronic diseases. Among these, diabetes can cause long term damage to the body other than having a relevant economic burden on society being among the costliest chronic diseases. This motivated the focus of the proposed Special Issue, intended to develop and exploit the potential role of plants in the management and treatment of diabetes. The main topics included are: (i) description and use of medicinal plants for diabetes management; (ii) the elucidation and delineation of their main components, properties (anti-hyperglycaemic, hypoglicaemic, anti-infiammatory, apoptotic agents, etc.), (iii) the mechanism of action (in vitro and in vivo studies); (iv) formulation of nutraceuticals, botanicals, and dietary supplements useful as tools as an alternative or support to anti-diabetic pharmacological therapies; (v) development of new markers.
Collapse
Affiliation(s)
- Alessandra Durazzo
- CREA-Research Centre for Food and Nutrition, via Ardeatina 546, 00178 Rome, Italy
| | - Massimo Lucarini
- CREA-Research Centre for Food and Nutrition, via Ardeatina 546, 00178 Rome, Italy
| | - Antonello Santini
- Department of Pharmacy, University of Napoli Federico II, via D. Montesano 49, 80131 Napoli, Italy
| |
Collapse
|